GOLD 2026 COPD Strategy: Mepolizumab Enters the Algorithm

GOLD 2026 adds mepolizumab as a second eosinophil-guided biologic option and refines exacerbation-focused escalation, expanding the pharmacist's role in phenotype-driven COPD care.

📅 Journal publication: Dec 8, 2025 · Last updated: Jul 21, 2026

GOLD 2026Global Initiative for Chronic Obstructive Lung DiseaseCOPDLABALAMAICSbiologicsmepolizumabdupilumabensifentrineroflumilastazithromycin COPD

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.

Subscribe for $8/month → Read this one free →

Free account, no credit card. Includes 1 full deep analysis every month.

View on PubMed →

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Founding member rate

$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →

Free account, no credit card. Includes 1 full deep analysis every month.

Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.